Related Experiment Video
Updated: May 5, 2026
Linear Amplification Mediated PCR – Localization of Genetic Elements and Characterization of Unknown Flanking DNA
Published on: June 25, 2014
Gene therapy: X-SCID transgene leukaemogenicity
Adrian J Thrasher1, H Bobby Gaspar, Christopher Baum
1Molecular Immunology Unit, Institute of Child Health, University College London, London WC1N 1EH, UK. a.thrasher@ich.ucl.ac.uk
Gene therapy can restore immune function but carries leukemia risks. This study suggests the therapeutic gene IL2RG may not be inherently oncogenic, questioning its role in human trial safety concerns.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- Gene therapy effectively reconstitutes immunity in severe combined immune deficiency (SCID) patients.
- Leukemia occurrence in some SCID patients post-gene therapy raises safety concerns and questions leukemogenesis mechanisms.
Discussion:
- Woods et al. observed tumors in a mouse model with forced high expression of the IL2RG gene.
- This study investigates the intrinsic oncogenic potential of the IL2RG gene.
- The interpretation of IL2RG's role in human trial leukemogenesis is critically examined.
Key Insights:
- Transgenic IL2RG does not inherently possess potent oncogenic properties.
- The direct link between IL2RG overexpression and leukemia development in human trials may be overstated.
- This research refines the understanding of gene therapy-induced leukemogenesis.
Outlook:
- Further research is needed to elucidate the precise mechanisms of leukemogenesis in gene therapy.
- Re-evaluation of safety protocols and risk-benefit analyses for SCID gene therapy is warranted.
- This study contributes to the ongoing debate on the safety and efficacy of gene therapy for primary immunodeficiencies.
More Related Videos
12:58Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
